In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery

Diabetes, Obesity and Metabolism

Volumn 1, Issue 2, 1999, Pages 75-86

  Reed, Michael J ^a,b   Scribner, Karen A ^a  

^a Shaman Pharmaceuticals Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CULTURE TECHNIQUE; DISEASE MODEL; DRUG SCREENING; HUMAN; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACEUTICS; RAT; REVIEW;

ANIMALS; CELLS, CULTURED; CULTURE TECHNIQUES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; MICE; MODELS, BIOLOGICAL; RATS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0033086342     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.00014.x     Document Type: Review

References (113)

1. Murray CLJ, Lopez AD. Global health statistics: a compendium of incidence, prevalence, and mortality estimates for over 200 conditions. Harvard School Public Health 1996; 588.
2. Kubinyi H. Strategies and recent technologies in drug discovery. Pharmazie 1995; 50; 647-662.
3. Maxwell RA. The state of the art of the science of drug discovery-an opinion. Drug Develop Res 1984; 4: 375-389.
4. Oubre AY, Carlson TJ, King SR, Reaven GM. From plant to patient: and ethnomedical approach to the identification of new drugs for the treatment of NIDDM. Diabetologia 1997; 40: 614-617.
5. Hummel KP, Dickie MM, Coleman DL. Diabetes, a new mutation in the mouse. Science 1966; 153: 1127-1128.
6. Chen H, Charlat O, Tartaglia LA et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495.
7. Hosokawa T, Ando K, Tamura G. An ascochlorin derivative, AS-6, reduces insulin resistance in the genetically obese diabetic mouse, db/db. Diabetes 1985; 34: 267-274.
8. Tasaka Y, Yanagisawa K, Iwamoto Y. Human plasma leptin in obese subjects and diabetics. Endocr J 1997; 44: 671-676.
9. Carantoni M, Abbasi F, Azhar S et al. Plasma leptin concentrations do not appear to decrease insulin-mediated glucose disposal or glucose-stimulated insulin secretion in women with normal glucose tolerance. Diabetes 1998; 47: 244-247.
10. Luo J, Fort DM, Carlson TJ et al. Cryptolepis sanguinolenta: an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycemic agent. Diabetic Med 1998; 15: 367-374.
11. Bierer DE, Dubenko LG, Zhang P et al. Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from cryptolepis sanguinolenta. J Med Chem 1998; 41: 2754-27641.
12. Bierer DE, Fort DM, Mendez CD et al. Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities. J Med Chem 1998; 41: 894-901.
13. Luo J, Chuang T, Cheung J et al. Masoprocol (nordihydroguaiaretic acid): a new antihyperglycemic agent isolated from the creosote bush (Larrea tridentata). Eur J Pharmacol 1998; 346: 77-79.
14. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995; 44: 486-490.
15. Connor SC, Hughes MG, Moore G, Lister CA, Smith SA. Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57?BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine. J Pharm Pharmacol 1997; 49: 336-344.
16. Kees MJ, Caggiano TJ, Steiner KE et al. Studies on new acidic azoles as glucose-lowering agents in obese, diabetic db/db mice. J Med Chem 1995; 38: 617-628.
17. Wrobel J, Li Z, Dietrich A et al. Novel 5-(3-aryl-2-propynyl) -5-(arylsulfonyl) thiazolidine-2,4-diones as antihyperglycemic agents. J Med Chem 1998; 41: 1084-1091.
18. Zhang B, Graziano MP, Doebber TW et al. Down-regulation of the expression of the obese gene by antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996; 271: 9455-9459.
19. Freund P, Wolff HP, Kuhnle HF. (-)-BM 13.0913: a new oral diabetic agent that improves insulin sensitivity in animal models of type II (non-insulin-dependent) diabetes mellitus. Metabolism 1995; 44: 570-576.
20. Ishikawa Y, Watanabe K, Takeno H, Tani T. Effects of the novel oral antidiabetic agent HQL-975 on glucose and lipid metabolism in diabetic db/db mice. Arzneimittelforschung 1998; 48: 245-250.
21. Liang Y, Jetton TL, Lubkin M, Meier AH, Cincotta AH. Bromocriptine/SKF38393 ameliorates islet dysfunction in the diabetic (db/db) mouse. Cell Mol Life Sci 1998; 54: 703-711.
22. Hashimoto K, Nagao Y, Ida K et al. Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*, R*) -(+/-) -methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl) ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents. Biochem Pharmacol 1996; 52: 1529-1535.
23. Kees KL, Fitzgerald JJ Jr, Steiner KE et al. New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl) pyrazoles and-pyrazolones. J Med Chem 1996; 39: 3920-3928.
24. Takeshita M, Yamaguchi I. Meta-chlorophenylpiperazine attenuates formalin-induced nociceptive responses through 5-HT1/2 receptors in both normal and diabetic mice. Br J Pharmacol 1995; 116: 3133-3138.
25. Takeshita N, Ohkubo Y, Yamaguchi I. Tiapride attenuates pain transmission through an indirect activation of central serotonergic mechanism. J Pharmacol Experiment Ther 1995; 275: 23-30.
26. Yamamoto T, Horikawa N, Komuro Y, Hara Y. Effect of topical application of a stable prostacyclin analogue, SM-10902 on wound healing in diabetic mice. Eur J Pharmacol 1996; 302: 53-60.
27. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14: 141-148.
28. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J. Positional cloning of the mouse ob gene and its human homologue. Nature 1994; 372: 425-432.
29. Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene [see comments]. Science 1995; 269: 543-546.
30. Sarges R, Hank RF, Blake JF et al. Glucose transport-enhancing and hypoglycemic activity of 2-methyl-2-phenoxy-3-phenylpropanoic acids. J Med Chem 1996; 39: 4783-4803.
31. Young PW, Cawthorne M.A, Coyle PJ et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 1995; 44: 1087-1092.
32. Foellmi LA, Wyse BM, Herron D, Nedergaard J, Kletzien RF. Induction of uncoupling protein in brown adipose tissue: synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent. Biochem Pharmacol 1996; 52: 693-701.
33. de Nanteuil G Herve Y, Duhault J, Espinal J, Boulanger M, Ravel D. Euglycemic and biological activities of novel thiazolidine-2,4-dione derivatives. Arzneimittelforschung 1995; 45: 1176-1181.
34. Arbeeny CM, Meyers DS, Hillyer DE, Bergquist KE. Metabolic alterations associated with the antidiabetic effect of beta 3-adrenergic receptor agonists in obese mice. Am J Physiol 1995; 268: E678-E684.
35. Parker JC, VanVolkenburg MA, Nardone NA, Hargrove DM, Andrews KM. Modulation ofsulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III. Biochem Biophys Res Comm 1997; 236: 665-669.
36. Lazarus DD, Trimble LA, Moldawer LL. The metabolic effects of pokeweek mitogen in mice. Metabolism 1998; 47: 75-82.
37. Parker JC, VanVolkenburg MA, Levy C et al. Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes 1998; 47: 1630-1636.
38. Murakami N, Ohta M, Hashimoto K et al. Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent. Eur J Pharmacol 1996; 304: 129-134.
39. Reddi AS, Camerini-Davalos RA. Hereditary diabetes in the KK mouse: an overview. Adv Experiment Med Biol 1988; 246: 7-15.
40. Ikeda H. KK mouse. Diabetes Res Clin Pract 1994; 24 (Suppl): S313-S316.
41. Kakuda T, Sakane I, Takihara T, Ozaki Y, Takeuchi H, Kuroyanagi M. Hypoglycemic effect of extracts from Lagerstroemia speciosa L. leaves in genetically diabetic KK-Ay mice. Biosci Biotechnol Biochem 1996; 60: 204-208.
42. Fukunaga T, Miura T, Furuta K, Kato A. Hypoglycemic effect of the rhizomes of Smilax glabra in normal and diabetic mice. Biol Pharm Bull 1997; 20: 44-46.
43. Izumi T, Enomoto S, Hoshiyama K, Sasahara K, Sugiyama Y. Pharmacokinetic stereoselectivity of troglitazone, an antidiabetic agent, in the KK mouse. Biopharm Drug Dispos 1997; 18: 241-257.
44. Izumi T, Hoshiyama K, Enomoto S, Sasahara K, Sugiyama Y. Determination of protein binding of troglitazone stereoisomers by fluorometric titration. Biopharm Drug Dispos 1997; 18: 305-324.
45. Izumi T, Hosiyama K, Enomoto S, Sasahara K, Sugiyama Y. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidatino from in vitro data. J Pharmacol Experiment Ther 1997; 280: 1392-1400.
46. Kawai K, Kawasaki Y, Tokui Y et al. Disposition and metabolism of the new antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 1997; 47: 356-368.
47. Tanis SP, Parker TT, Colca JR, Fisher RM, Kletzein RF. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. J Med Chem 1996; 39: 5053-5063.
48. Arakawa K, Inamasu M, Matsumoto M et al. Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships. Chem Pharm Bull (Tokyo) 1977; 45: 1984-1993.
49. Ueda N, Nomura Y, Muta Y et al. Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5-(4-(1-phenyl-1-cyclopropanecarbonylamino) benzyl) -thiazolidine-2,4-dione. Arzneimittelforschung 1998; 48: 651-657.
50. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995; 28 (Suppl): S115-S137.
51. Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 1996; 28: 469-487.
52. Morimoto Y, Nishikawa K, Ohashi M. KB-R77785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci 1997; 61: 795-803.
53. Reaven GM, Ho H. Low-dose streptozotocin-induced diabetes in the spontaneously hypertensive rat. Metabolism 1988; 37: 303-305.
54. Luo J, Quan J, Tsai J et al. Nongenetic mouse models of non-insulin dependent diabetes mellitus. Metabolism 1998; 47: 663-668.
55. Reed MJ, Meszaros K, Entes LJ et al. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of type II diabetes. Diabetologia 1999; 41: in press.
56. Moeller DE. Transgenic approaches to the pathogenesis of NIDDM. Diabetes 1994; 43: 1394-1401.
57. Grewal IS, Flavell RA. New insights into insulin dependent diabetes mellitus from studies with transgenic mouse models. Lab Invest 1997; 76: 3-10.
58. White BD, Martin RJ. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proceed Soc Experiment Biol Med 1997; 214: 222-232.
59. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995; 44: 863-870.
60. Turner NC, White P. Effects of streptozotocin-induced diabetes on vascular reactivity in genetically hyperinsulinemic obese Zucker rats. J Cardiovasc Pharmacol 1996; 27: 884-890.
61. de Souza CJ, Yu JH, Robinson DD, Ulrich RG, Meglasson MD. Insulin secretory defect in Zucker fa/ fa rats is improved by ameliorating insulin resistance. Diabetes 1995; 44: 984-991.
62. Yamamoto H, Takakura S, Yamamoto T et al. FR149175: a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol 1997; 74: 109-112.
63. Peterson RG, Shaw WN, Neel M-A, Little LA, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR News (hist Lab Animal Res) 1990; 32: 16-19.
64. Paulik MA, Hamacher LL, Yarnall DP et al. Identification of Rad's effector-binding domain, intracellular localization, and analysis of expression in Pima Indians. J Cell Biochem 1997; 65: 527-541.
65. Clark RG, Thomas GB, Mortensen DL et al. Growth hormone secretagogues stimulate the hypothalamic-pituitary-adrenal axis and are diabetogenmic in the Zucker diabetic fatty rat. Endocrinology 1997; 138: 4316-4323.
66. Hargrove DM, Nardone NA, Persson LM, Parker JC, Stevenson RW. Glucose-dependent action of glucagon-like-peptide-1 (7-37): in vivo during short-or long-term administration. Metabolism 1995; 44: 1231-1237.
67. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z. A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 1981; 30: 1045-1050.
68. Hayakawa T, Shiraki T, Morimoto T, Shii K, Ikeda H. Pioglitazone improves insulin signalling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Comm 1996; 223: 439-444.
69. Murase K, Odaka H, Suzuki M, Tayuki N, Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 1998; 41: 257-264.
70. Ikeda H, Odaka H. AO-128, alpha-glucosidase inhibitor: antiobesity and antidiabetic actions in genetically obese-diabetic rats, Wistar fatty. Obesity Res 1995; 3 (Suppl): S617-S621.
71. Shibouta Y, Chatani F, Ishimura Y et al. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Intl 1996; 55(Suppl): S115-S118.
72. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clinical Pract 1994; 24 (Suppl): S317-S320.
73. Anderson RC, Balestra M, Bell PA et al. Antidiabetic agents: a new class of reversible carnitine palmitoyltransferase I inhibitors. J Med Chem 1995; 38: 3448-3450.
74. Ikenoue T, Okazaki K, Fujitani S et al. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharm Bull 1997; 20: 354-359.
75. Jones RB, Dickinson K, Anthony DM, Marita AR, Kaul CL, Buckett WR. Evaluation of BTS 67, 582, a novel antidiabetic agent, in normal and diabetic rats. Br J Pharmacol 1997; 120: 1135-1143.
76. Ohnota H, Koizumi T, Kobayashi M, Momose Y, Sato F. Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S) -2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats. Can J Physiol Pharmacol 1995; 73: 1-6.
77. Ohnota H, Kitamura T, Kinukawa M et al. A rapid and short-acting hypoglycemic agent KAD-1229 improves post-pranidal hyperglycemic and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Jpn J Pharmacol 1996; 71: 315-323.
78. Kinukawa M, Ohnota H, Ajisawa Y. Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229, on hormone secretion in the isolated perfused pancreas of the rat. Br J Pharmacol 1996; 117: 1702-1706.
79. Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
80. Angel I, Burcelin R, Proteau M, Girard J, Langer SZ. Normalization ofsulin secretion by a selective alpha 2-adrenoceptor antagonist restores GLUT-4 glucose transporter expression in adipose tissue of type II diabetic rats. Endocrinology 1996; 137: 2022-2027.
81. Ishikawa J, Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Hypoglycemic and hypotensive effects of 6-cyclohexyl-2′-O-methyl adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res Clin Pract 1998; 39: 3-9.
82. 9+ glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo) 1996; 44: 1174-1180.
83. Tsutsumi K, Inoue Y, Shima A, Murase T. Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 1995; 44: 414-417.
84. Sakuma Y, Hagihara H, Nagayoshi A et al. Effects of FR145237, an acyl-CoA: cholesterol acyltransferase inhibitor, on diet-induced hypercholesterolemia in diabetic rats. Life Sci 1997; 60: 351-356.
85. Nakayama K, Murakami N, Ohta M et al. Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats. Eur J Pharmacol 1995; 276: 77-83.
86. Nakayama K, Murakami N, Ohta M et al. Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats. Eur J Pharmacol 1995; 276: 85-91.
87. Field MJ, McCleary S, Boden P, Suman-Chauhan N, Hughes J, Singh L. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat. J Pharmacol Experiment Ther 1998; 285: 1226-1232.
88. Uehara K, Sugimoto K, Wada R et al. Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. J. Diabetes Complications 1997; 11: 194-202.
89. B'ir'o K., Jedn'akovits A., Kukorelli T., Hegedus E., Kor'anyi L. Bimoclomol (BRLP-42) ameliorates peripheral neuropathy in streptozotocin-induced diabetic rats. Brain Res Bull 1997; 44: 259-263.
90. Miyauchi Y, Shikama H, Tadasu T et al. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozotocin-induced diabetic rats. Eur J Endocrinol 1996; 134: 467-473.
91. Kochakian M, Manjula BN, Egan JJ. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes 1996; 45: 1694-1700.
92. Yamano M, Kamato T, Nagakura Y, Miyata K. Effects of gastroprokinetic agetns on gastroparesis in streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 1997; 356: 145-150.
93. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, Maki T. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br J Pharmacol 1997; 120: 137-145.
94. Hargrove DM, Nardone NA, Persson LM et al. Comparison of the glucose dependency of glucagon-like peptide-1(7-37): and glyburide in vitro and in vivo. Metabolism 1996; 45: 404-409.
95. Gromada J, Dissing S, Kofod H, Frokjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995; 38: 1025-1032.
96. Martin WH, Hoover DJ, Armento SJ et al. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proceed Natl Acad Sci USA 1998; 95: 1776-1781.
97. Pittner RA, Wolfe Lopez D, Young AA, Rink TJ. Amylin and epinephrine have no direct effect on glucose transport in isolated rat soleus muscle. FEBS Letts 1995; 365: 98-100.
98. Beaumont K, Pittner RA, Moore CX et al. Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved. Br J Pharmacol 1995; 115: 713-715.
99. Muller G, Wied S, Piossek C, Bauer A, Bauer J, Frick W. Convergence and divergence of the signaling pathways for insulin and phosphoinositolglycans. Mol Med 1998; 4: 299-323.
100. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996; 28: 496-507.
101. Cox BF, Clark KL, Perrone MH et al. Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol 1997; 29: 417-426.
102. Mayers RM, Quayle SP, Thompson AJ, Grant TL, Holloway BR. The acid metabolite of ZD7114 is a partial agonist of lipolysis mediated by the rat beta 3-adrenoceptor. Eur J Pharmacol 1996; 295: 199-205.
103. Paulik MA, Buckholz RG, Lancaster ME et al. Development offrared imaging to measure thermogenesis in cell culture: thermogenic effects of uncoupling protein-2, troglitazone, and beta-adrenoceptor agonists. Pharm Res 1998; 15: 944-949.
104. Tafuri SR. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 1996; 137: 4706-4712.
105. Su TZ, Wang M, Oxender DL, Saltiel AR. Troglitazone increases system A amino acid transport in 3T3-L1 cells. Endocrinology 1998; 139: 832-837.
106. Young PW, Buckle DR, Cantello BC et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Experiment Ther 1998; 284: 751-759.
107. Wiesenberg I, Chiesi M, Missbach M, Spanka C, Pignat W, Carlberg C. Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608. Mol Pharmacol 1998; 53: 1131-1138.
108. Mizukami J, Taniguchi T. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP. Biochem Biophys Res Comm 1997; 240: 61-64.
109. Stevenson RW, McPherson RK, Persson LM et al. The antihyperglycemic agent englitazone prevents the defect in glucose transport in rats fed a high-fat diet. Diabetes 1996; 45: 60-66.
110. Stevenson RW, Kreutter DK, Andrews KM, Genereux PE, Gibbs EM. Possibility of distinct insulin-signaling pathways beyond phosphatidylinositol 3-kinase-mediating glucose transport and lipogenesis. Diabetes 1998; 47: 179-185.
111. Szalkowski D, White-Canington S, Berger J, Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995; 136: 1474-1481.
112. Lehmann JM, Moore LB, Smith Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
113. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997; 54: 801-880.